Independent Digital Healthcare Regulatory & Operational Due Diligence Before Investment or Acquisition
Oxara Consulting provides independent regulatory and operational due diligence for digital healthcare transactions, including online clinics, remote prescribing services, digital diagnostics, technology-enabled care and other remotely delivered healthcare models. We examine whether the target's CQC position, clinical governance, digital clinical-safety arrangements, prescribing controls and operational evidence support the service being presented to a purchaser, investor, lender or professional adviser.
A digital healthcare service can look efficient on screen and still carry material clinical and regulatory risk underneath it.
Digital healthcare is rarely one system and one regulator. A single operating model may combine online consultations, prescribing, diagnostics, patient questionnaires, automated triage, clinical decision support, outsourced pharmacy arrangements, third-party software, remote clinicians, data processing and escalation into face-to-face or emergency care.
That creates a transaction risk which cannot be understood by reading a CQC rating, reviewing a policy folder or checking that contracts exist. The question is whether the service that is actually being delivered is the service that is registered, governed, clinically controlled and evidenced.
Oxara Consulting provides independent regulatory and operational due diligence for buyers, investors, lenders and professional advisers who need to understand that position before completion. We examine what is documented, what is implemented and where the two do not join up.
Is the target business merely able to describe a compliant digital healthcare model, or can it demonstrate that the model is controlled, embedded and capable of standing up to regulatory scrutiny after ownership changes?
For transactions where healthcare risk sits behind the financial model
We may be instructed directly by a purchaser, investor or lender, or alongside solicitors, corporate-finance advisers and other professional teams. The review is particularly relevant where the value of the business depends on continued regulatory registration, safe remote clinical delivery, scalable prescribing, technology-enabled pathways or a network of third-party providers.
- acquisition of an online clinic or digital healthcare provider;
- investment into an existing regulated service or digital clinical platform;
- lender due diligence where regulatory failure could affect service continuity or value;
- acquisition of a service using remote prescribing, digital diagnostics or remote monitoring;
- integration of a digital service into a wider healthcare group;
- market entry where the proposed operating model needs to be tested against UK healthcare requirements.
If the transaction depends on the target remaining clinically safe, correctly regulated and operationally defensible after completion, the due diligence should test more than the documents supplied in the data room.
Discuss a Digital Health TransactionThe regulatory perimeter depends on what the digital healthcare service actually does.
Where regulated activities are carried on in England, the starting point is the Health and Social Care Act 2008 framework, the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 and the provider's CQC registration. For online primary care, the operating model also needs to be read against CQC's current expectations for online services, including the evidence required to support registration.
But CQC is only one layer. Remote prescribing must operate within the professional standards applying to the clinicians involved. Digital clinical systems may bring DCB0129 or DCB0160 clinical-risk-management evidence into scope. Software or AI performing a medical purpose may raise medical-device questions under the MHRA framework. Health information is special-category personal data, and NHS-facing services may also depend on wider information-governance, cyber-security and assurance requirements.
The due-diligence task is therefore not to apply every digital-health standard to every company. It is to establish which requirements are relevant to the target's actual model, then test whether the evidence demonstrates control of those risks.
From registration to the point where a patient receives care
1. Regulatory Position and Service Model
We establish what the provider is registered to do, what it says it does and what the operational evidence shows it actually does. This includes regulated activities, registered locations, conditions of registration where relevant, service pathways, geographic reach, regulatory history and any material difference between the registered model and the live service.
2. Clinical Governance and Board Assurance
Policies are not treated as proof of governance. We look for evidence that responsibility is allocated, risks are escalated, incidents and complaints are analysed, audit findings are acted upon and senior oversight can demonstrate a line from information to decision to improvement. Where the service has grown quickly, we test whether governance has scaled with activity rather than remained designed for an earlier, smaller operation.
3. Remote Consultation, Prescribing and Medicines
Where prescribing forms part of the model, we review how the provider controls patient identification, clinical assessment, access to relevant information, consent, contraindications, monitoring, prescribing thresholds, escalation, continuity of care and communication with other healthcare professionals. We also examine how prescriber performance and medicines-related risk are overseen.
Where dispensing or pharmacy fulfilment is outsourced, we consider how responsibilities are divided, how information passes between organisations and whether the provider can evidence effective oversight rather than relying on the existence of a commercial contract.
4. Workforce, Credentialing and Clinical Accountability
Digital delivery can distribute clinical work across employed, sessional, contracted and remote clinicians. We examine professional registration checks, role definition, induction, competence, supervision, appraisal, access to clinical support and the arrangements for identifying deteriorating performance. The review asks who is accountable for the clinical decision, who supervises the system around that decision and whether those responsibilities remain clear when care crosses organisational boundaries.
5. Safeguarding, Deterioration and Escalation
A remote pathway must recognise when remote care is no longer sufficient. We test how the service identifies vulnerable patients, safeguarding concerns, medical emergencies, deterioration, exclusion criteria and circumstances requiring face-to-face assessment or referral. Where algorithms, questionnaires or non-clinical triage influence access, we look at how clinical risk is controlled when the patient does not fit the expected pathway.
6. Digital Clinical Safety
Where relevant to the technology and deployment model, we review the presence and governance of clinical-risk-management evidence, including hazard identification, risk controls, clinical safety cases, hazard logs, change control and the role of the Clinical Safety Officer. DCB0129 and DCB0160 are considered where applicable; Oxara does not certify compliance with those standards.
A particular focus is whether the documented safety case still reflects the live product. A system may have been assessed when introduced but subsequently changed through new workflows, integrations, automation or AI-enabled features. Due diligence should identify whether clinical-safety governance has kept pace with that change.
7. Software, AI and Medical-Device Questions
Software used merely to administer a service presents a different regulatory question from software that performs or materially influences a medical purpose. Where functionality suggests that medical-device regulation may be engaged, we identify the issue and the evidence requiring specialist technical, regulatory or legal review. We do not provide medical-device legal classification.
8. Records, Information Governance and Data Dependencies
We examine the operational governance around clinical records, access, data flows, third-party processors, retention, information-sharing and continuity of access to information required for safe care. This is not a substitute for specialist data-protection or cyber-security due diligence; the purpose is to identify where information arrangements create a healthcare-delivery or governance risk.
9. Third-Party and Outsourced Dependencies
Digital healthcare businesses often depend on suppliers that sit directly inside the care pathway: pharmacies, laboratories, diagnostic providers, hosting and software vendors, call-handling services, contracted clinicians and referral partners. We test whether the provider understands those dependencies, has clear accountability arrangements and can demonstrate oversight of risks that cannot simply be transferred by contract.
10. Public Claims and the Reality of the Service
Website copy, patient journeys and investor materials can reveal material inconsistencies. We compare public claims about clinicians, treatments, turnaround times, access, technology and service capability with the regulatory and operational evidence available. A mismatch may indicate anything from poor marketing governance to a more fundamental difference between the business being presented and the business being operated.
The existence of a policy is not the same as evidence that the control works.
Digital healthcare transactions can produce substantial data rooms. Volume does not necessarily equal assurance. A provider may have policies, dashboards, audit schedules and governance terms of reference while still being unable to show that identified risks are followed through, that clinical learning changes practice or that controls operate consistently across the service.
Oxara tests the connection between documents and operational evidence. Where appropriate, we trace issues across records: from an incident to investigation, from investigation to action, from action to audit, and from audit to evidence that the change has been sustained. The same principle is applied to prescribing concerns, complaints, safeguarding, workforce issues and technology-related clinical risk.
This matters to a purchaser because weaknesses that have not yet produced regulatory action can still become inherited liabilities after completion.
A transaction-focused review, proportionate to the risk and the evidence available
1. Define the Transaction and Regulatory Perimeter
We establish the target structure, service lines, regulated activities, digital pathways, relevant locations, technology dependencies and the purpose of the instruction. This prevents a generic compliance review being applied to a transaction that may have very specific risk questions.
2. Review the Evidence
We examine the available regulatory, governance and operational documentation and identify what is confirmed, what is absent and what requires clarification. Depending on scope, this can include regulatory correspondence, governance records, audits, incidents, complaints, prescribing information, workforce evidence, clinical-safety documentation, supplier arrangements and operational performance information.
3. Test Areas of Heightened Risk
Where the evidence does not join up, we do not fill the gap by assumption. We identify the issue, seek clarification where agreed and distinguish between an evidenced control, an asserted control and a matter that remains unverified. Targeted sampling or management clarification can be used where proportionate.
4. Report in Transaction Language
Findings are structured so that the purchaser and professional team can understand significance, not simply receive a list of regulatory references. The report identifies material risk, the evidence relied upon, unresolved questions, potential post-completion implications and matters requiring input from legal, financial, technical, tax or other advisers.
A defensible picture of the regulatory and operational position — including what cannot yet be verified
- a written independent regulatory and operational due-diligence report;
- analysis of the target's CQC position and regulatory history where applicable;
- assessment of clinical-governance and operational-control evidence;
- identification of material risks, inconsistencies and evidence gaps;
- clear separation between verified evidence, management assertion and matters not verified;
- transaction questions requiring further clarification before completion;
- identification of matters requiring legal, financial, tax, technical, cyber-security, data-protection, medical-device or other specialist input;
- where agreed, prioritisation of issues which may require immediate post-completion control or integration planning.
Risks that may not be visible in the headline CQC position
A provider can hold registration and still present material transaction risk. Examples include:
- the registered model no longer reflecting the way care is actually delivered;
- rapid growth without equivalent development of clinical governance and oversight;
- remote-prescribing controls that are documented but inconsistently applied;
- unclear accountability between the provider, prescribers, pharmacies, laboratories or technology suppliers;
- clinical incidents or complaints which have been closed administratively without demonstrable learning;
- weak escalation from digital pathways into urgent, face-to-face or emergency care;
- clinical-safety documentation that does not reflect the current system or recent product changes;
- software functionality which may require medical-device assessment that has not been addressed;
- information flows or supplier dependencies capable of disrupting continuity of care;
- public claims about the service that are not supported by the underlying operating model;
- a governance framework which depends materially on individuals who may leave after the transaction;
- integration risk capable of destabilising a currently functioning service after acquisition.
A good rating, a polished platform and a complete policy suite are useful evidence. None of them, on their own, establishes that the service is safe to acquire.
Discuss Your TransactionWhy digital healthcare due diligence cannot stop at CQC
CQC registration, inspection findings and enforcement history are central to understanding a regulated provider, but they are not a complete transaction opinion. A digital service may also depend on professional prescribing standards, clinical-safety controls, software functionality, medical-device questions, health-data processing, cyber-security, pharmacy or laboratory relationships and the resilience of third-party systems.
The important issue is how those elements combine in the live care pathway. A weakness outside the narrow CQC record can still become a patient-safety, continuity, reputational or regulatory problem for the purchaser.
Oxara's role is to examine that interaction from a healthcare regulatory and operational perspective and to identify the point at which another qualified specialist needs to be brought into the transaction. We do not provide legal, financial, tax, investment, medical-device legal or cyber-security advice, and we do not decide whether a transaction should proceed.
Related Digital Health and Transaction Services
Questions professional clients commonly need answered before completion
What is digital healthcare regulatory and operational due diligence?
It is an independent examination of the regulatory position, clinical governance, operational controls and material healthcare risks associated with a digital healthcare provider before acquisition, investment, financing or another transaction. The purpose is to establish what the available evidence supports and what remains uncertain or requires further investigation.
Is a good CQC rating enough to give a purchaser assurance?
No. It is relevant evidence, but it is only one part of the picture. The service may have changed since inspection, expanded into new pathways, introduced new technology or prescribing models, changed key personnel, or developed third-party dependencies that are not apparent from the public rating alone.
How is this different from legal due diligence?
Legal due diligence considers legal rights, obligations, contracts and other legal matters. Oxara examines the healthcare regulatory and operational evidence: how the service is structured, governed and delivered in practice, and what risks a purchaser may inherit. The two disciplines are complementary rather than interchangeable.
Can Oxara review an online prescribing business?
Yes. Where relevant to the instruction, the review can examine the service model, remote consultation and prescribing governance, patient identification, clinical assessment, monitoring, medicines oversight, escalation, continuity of care and the governance of pharmacy or other third-party relationships.
What if software or AI may be a medical device?
Oxara can identify functionality or operating arrangements that raise a medical-device due-diligence question and can assess the operational significance of that issue. Formal medical-device classification or legal interpretation should be undertaken by an appropriately qualified specialist.
Do you review DCB0129 and DCB0160 evidence?
Where those standards are relevant to the target and the agreed scope, we can review the presence, governance and operational use of clinical-safety evidence such as hazard logs, safety cases, risk controls and change-management arrangements. Oxara does not certify DCB0129 or DCB0160 compliance.
Can the review identify issues that are not yet CQC enforcement matters?
Yes. Due diligence is not limited to existing enforcement. A transaction may carry material risk because governance is weak, evidence is incomplete, clinical controls are fragile or the operating model has moved ahead of the provider's assurance systems even where no formal enforcement action has occurred.
Who can instruct Oxara?
Instructions may come from purchasers, investors, lenders, solicitors, corporate-finance advisers, healthcare groups or other professional advisers requiring independent healthcare-sector regulatory and operational evidence.
Does Oxara advise whether the buyer should proceed?
No. We provide independent regulatory and operational evidence, explain material risks and identify matters requiring further specialist input. The investment or acquisition decision remains with the client and its professional advisers.
Understand what you would be acquiring before the transaction completes.
Disclaimer
Oxara Consulting is a professional consultancy, not a legal firm. Please see our full Disclaimer for more information.